Lilly Wants Records of People Who Took Weight-Loss Knockoffs
Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their medical records as it continues to build a case against businesses selling the compounded drugs.
Eli Lilly wants records of people who took copies of its weight-loss drug
“I am gobsmacked that Lilly is seeking confidential patient medical records to build a case against the very therapies that are benefiting those patients at a time when Lilly’s own drugs are not available to those patients,” said Scott Brunner, chief executive officer of the Alliance for Pharmacy Compounding, an industry trade group.
Health Rounds: Next generation Lilly weight-loss drug shows added heart, liver benefits
Eli Lilly's experimental next generation weight-loss drug mimics three hormones instead of just one or two and continues to show promising clinical trial results for additional health benefits, the company said.
Weight loss market: Smaller rivals muscle in on Eli Lilly and Novo Nordisk
As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up to release their own treatments, aiming to challenge the two industry leaders.
Eli Lilly Names New CFO Amid Weight-loss Drug Expansion Plan
U.S. pharmaceutical giant Eli Lilly named a new chief financial officer on Monday during a critical time for the company's exploding weight-loss drug market.
Lilly weight loss drug prevents diabetes, company says
Lilly also sells tirzepatide under the brand name Mounjaro, to treat people with diabetes, though they typically lose less weight than people without the disease. The list price of both Mounjaro and Zepbound runs about $1,000, though coupons and discounts can reduce the cost
Eli Lilly request records of people who took copies of its weight-loss drug
The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell the compounded versions has intensified.
Lilly asks people who took compounded tirzepatide for their medical records
Eli Lilly (NYSE:LLY) is taking the unusual step of asking people who took compounded versions of their drug tirzepatide, marketed as Zepbound for weight loss and Mounjaro for type 2 diabetes, for medical records to examine potential safety concerns.
The Price War in Weight-Loss Drugs Is Here
Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...
Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)
Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...
U.S. weight-loss medicine makers cut prices for insurance inclusion: WSJ
Eli Lilly and Novo Nordisk the pharmaceutical heavyweights selling popular weight-loss injections are each dangling discounts to gain an edge and to ...
This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk's and Eli Lilly's Weight Loss Treatments
In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...